Trevi Therapeutics TRVI 深 滬
等待開盤 08-01 09:30:00 美东时间
7.405
-0.015
-0.20%
華盛通- 最 高7.6091
- 今 開7.35
- 成交量 113.37万股
- 最 低 7.32
- 昨 收 7.42
- 總市值 9.03亿
- 52周最高 8.11
- 市盈率 靜 --
- 換手率 0.93%
- 52周最低 2.36
- 委 比 3.58%
- 總股本 1.22亿
- 歷史最高 10.62
- 量 比 0.52
- 振 幅 3.90%
- 歷史最低 0.46
- 每 手 1
- 風險率 0.75%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Trevi Therapeutics to Participate in Upcoming August Conferences
NEW HAVEN, Conn., July 29, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalb...
07-29 19:30
美股大行评级 | 潜在涨幅83.3%！Robinhood获Keybanc升目标价至110美元，维持"超配"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners：维持再鼎医药(ZLAB)"跑赢大市"评级，目标价从73美元升至75美元</p> <p>• 美银证券：维持BioCryst Pharma(BCRX)"买入"评级，目标价从13美元升至15美元
07-02 09:54
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism
NEW HAVEN, Conn., July 1, 2025 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbu...
07-01 19:30
Trevi Therapeutics Stockholders Approve Key Amendments
Trevi Therapeutics ( ($TRVI) ) just unveiled an announcement. On June 11, 2025,...
06-18 05:29
Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside
Tvardi advances fibrosis drug TTI-101 in IPF and liver cancer as Piper initiates with $78 target; merger boosts cash runway into late 2026.
06-13 03:08
Trevi Therapeutics Announces Public Offering Pricing
Trevi Therapeutics ( ($TRVI) ) has issued an update. On June 3, 2025, Trevi The...
06-05 04:51
Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial
Sionna's CF drug candidates SION-719 and SION-451 showed strong safety and PK results in Phase 1 trials, advancing to mid-stage studies in 2025.
06-05 01:54
Trevi Therapeutics prices $100M stock at $5.75 per share
Clinical-stage biopharmaceutical company Trevi Therapeutics (NASDAQ:TRVI) priced previously announced underwritten public offering of 17.4M shares at a public offering price of $5.75 per share. Tota...
06-04 12:24
美股大行评级 | 再生元制药遭大摩下调评级，Aspen Insurance Hldgs(AHL)获多家机构首予“超配”评级！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1136585934532136961.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Vera Therapeutics(VERA)"买入"评级，目标价从75美元升至85美元</p> <p>• Ascendiant Capital：维持60 Degrees
06-03 09:06
Trevi Therapeutics Terminates ATM Prospectus with Leerink
Trevi Therapeutics ( ($TRVI) ) just unveiled an update. On June 2, 2025, Trevi ...
06-03 04:42
